drugset / Trial / NCT01950741

Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy

NCT01950741

Phase 4 Completed 48 enrolled Pusan National University Hospital Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.

Timeline

Start
2013-09
Primary completion
2015-05
Completion
2015-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal